Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2014
At a glance
- Drugs FE 992097 (Primary)
- Indications Deglutition disorders; Prader-Willi syndrome
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 19 Aug 2014 Status changed from recruiting to completed as reported by the ClinicalTrials.gov.
- 09 Apr 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 as reported by the ClinicalTrials.gov.
- 27 Jan 2014 Status changed from not yet recruiting to recruiting as reported by the ClinicalTrials.gov record.